Neurocrine biosciences announces u.s. fda approval of ingrezza® sprinkle (valbenazine) capsules

San diego , april 30, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the u.s. food and drug administration has approved ingrezza® sprinkle (valbenazine) capsules, a new oral granules formulation of ingrezza® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with huntington's disease.1 ingrezza sprinkle provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. like the original formulation of ingrezza capsules, ingrezza sprinkle offers simple dosing that's always one capsule, once daily with no complex titration.1 ingrezza is the only selective vesicular monoamine transporter 2 (vmat2) inhibitor that offers three effective dosages (40 mg, 60 mg and 80 mg) that can be adjusted by the healthcare provider based on patient response and tolerability.1 ingrezza sprinkle offers the same dosage strengths, and the contents of the capsules can be easily sprinkled on soft food for oral administration.
NBIX Ratings Summary
NBIX Quant Ranking